News

Yale New Haven Children’s Hospital Clinic Named Certified Duchenne Care Center

Yale New Haven Children’s Hospital’s (YNHCH) Muscular Dystrophy Program has been named a Certified Duchenne Care Center by Parent Project Muscular Dystrophy (PPMD), a nonprofit organization dedicated to ending Duchenne muscular dystrophy (DMD). PPMD’s Certified Duchenne Care Center Program, which was started in 2014, supports standardized, comprehensive…

EU Grants Orphan Drug Status to Benitec’s Therapy for Oculopharyngeal MD

The European Commission has granted Orphan Drug Designation to Benitec Biopharma’s BB-301, an investigational treatment for oculopharyngeal muscular dystrophy (OPMD). The decision represents a major advance for OPMD, a rare congenital myopathy, for which the currently used therapeutic strategies involve repetitive surgical interventions that have limited effectiveness. Orphan Drug…

CureDuchenne Cares Announces Family Workshops, Therapist Training Sessions for 2017

CureDuchenne Cares, a community-based program providing educational and outreach workshops for parents and others caring for people with Duchenne muscular dystrophy (DMD), has just announced its planned events for 2017. CureDuchenne, the non-profit DMD research support organization, pioneered the Cares program to address a perceived urgent need to educate DMD families…

Translarna Renewed for Use by Nonsense Mutation Duchenne MD Patients in Europe

The European Commission (EC) has decided to renew the conditional marketing authorization for Translarna (ataluren) to treat certain nonsense mutation Duchenne muscular dystrophy (nmDMD) patients. PTC Therapeutics can now market Translarna for nmDMD patients who are 5 or older, mobile, and living in the European Union, Iceland, Liechtenstein, and Norway. The decision follows a…